All In Biotech

Drug Trial Radar · NCT06868628

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

5

Planned (sponsor's estimate)

Start

May 19, 2025

Primary completion

Apr 1, 2027

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Tiziana Life Sciences LTDIndustry
Sponsor type
Industry
First posted
Mar 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)

Conditions

  • Multiple System Atrophy

Interventions

  • Foralumab NasalDrug

    Foralumab is an anti-CD3 monoclonal antibody administered as a nasal spray. Participants will complete eight 3-week dosing cycles over the study. During each cycle, Foralumab will be administered intranasally three times per week for the first two weeks, with no administration in the third week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Screening to Month 6 in the total MDS-UMSARS scoreTime frame: From Screening to Month 6
  2. Change in TSPO activity as measured by [F-18]PBR06 retention calculated over whole brain and within key regions of interest (ROIs) at 6 months as compared to screeningTime frame: From Screening to Month 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.